TrialNature medicine2025

Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial.

Brian I Rini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.